2019
Corrigendum to “Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder” [Drug Alcohol Depend. 186 (2018) 171–174]
Holt SR, Donroe JH, Cavallo DA, Tetrault JM. Corrigendum to “Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder” [Drug Alcohol Depend. 186 (2018) 171–174]. Drug And Alcohol Dependence 2019, 205: 107601. PMID: 31593815, DOI: 10.1016/j.drugalcdep.2019.107601.Peer-Reviewed Original Research
2018
Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder
Holt SR, Donroe JH, Cavallo DA, Tetrault JM. Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder. Drug And Alcohol Dependence 2018, 186: 171-174. PMID: 29579725, DOI: 10.1016/j.drugalcdep.2017.12.040.Peer-Reviewed Original ResearchConceptsOngoing illicit drug usePatient-provider relationshipOpioid use disorderIllicit drug useUse disordersUrine adulterationTreatment planDrug useQuantitative urine testingMethadone treatment programsSubstance use disordersNorbuprenorphine levelsUrine buprenorphineUrine testingPatientsTreatment programNonjudgmental approachUrine samplesTherapeutic allianceDiscordant levelsBuprenorphineDisordersUrineNorbuprenorphineLevels